– Malignant melanoma follows a more aggressive course in HIV-seropositive patients than in HIV-seronegative patients, according to a report in the June issue of the Archives of Dermatology. Though previous reports have suggested an increased incidence of malignant melanoma among patients infected with HIV-1, the authors explain, only a few have commented on its outcome in such patients.
Dr. Mohammed Kashani-Sabet from University of California at San Francisco and colleagues reviewed the clinical course of 17 HIV-positive patients with malignant melanoma and compared it with that of 34 age- and sex-matched HIV-negative melanoma patients.
The subjects were matched for tumor thickness, subtype and other factors. Seven of 14 HIV-positive patients who were followed for a median of 48 months developed metastatic melanoma, the authors report, compared with 12 of 18 HIV-negative controls.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!